507 / 1631
o
Even low doses to normal tissues, previously considered safe,
may result in significant risks of morbidity in long-term survivors
o
Doses to all normal structures should be kept as low as possible
(some structures are more critical than others)
o
No two lymphomas are the same with regard to localization and
extent of disease (individual patient/target geometry)
o
The decision should be made at the individual patient level
(degree of modulation; individual treatment goals and toxicity
considerations)
Choosing wisely…